Hospital
Sharp Chula Vista Medical Center
Sharp Chula Vista Medical Center was paid $137.52M by Medicaid between Jan 2018 and Dec 2024, across 307 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoSHARP CHULA VISTA MEDICAL CENTER
CHULA VISTA, CA 91911
CHULA VISTA, CA 91911
33aNPI1396728630assigned 11/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$137.52M
24GClaims1,386,238
24DCodes billed307
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#11 of 410
Median peer was paid$6.90M
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 210,033 | $18.86M | |
| 2019 | 209,143 | $18.40M | |
| 2020 | 163,118 | $14.43M | |
| 2021 | 211,225 | $19.39M | |
| 2022 | 233,783 | $23.55M | |
| 2023 | 222,928 | $25.53M | |
| 2024incomplete | 136,008 | $17.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 61,881 | 57,335 | $28.53M |
| 0450 | Emergency room services | 15% | 69,235 | 63,188 | $20.06M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 12,559 | 12,291 | $9.31M |
| 99499 | 5.2% | 24,413 | 20,193 | $7.21M | |
| 80053 | Comprehensive metabolic panel | 3.5% | 120,247 | 110,115 | $4.88M |
| 0360 | 3.5% | 4,490 | 2,805 | $4.76M | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 15,180 | 14,819 | $4.00M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 61,044 | 54,498 | $3.55M |
| 99199 | Unlisted special service, procedure or report | 2.5% | 5,065 | 4,341 | $3.46M |
| 0206 | 2.3% | 274 | 249 | $3.17M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.0% | 9,997 | 9,212 | $2.70M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 5,701 | 5,583 | $2.49M |
295 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 123,169 | $2.34M |
| 99285 | Emergency room visit (most serious) | 1.6% | 6,197 | $2.24M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 27,469 | $2.10M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 18,875 | $2.01M |
| 59025 | Fetal non-stress test | 1.3% | 11,669 | $1.80M |
| 71045 | Radiologic examination, chest; single view | 1.3% | 37,954 | $1.74M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.3% | 14,278 | $1.74M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 3,289 | $1.66M |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,651 | $1.09M |
| 0762 | <1% | 2,678 | $1.09M | |
| 84484 | <1% | 35,027 | $1.01M | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 16,691 | $891K |
| 81001 | <1% | 57,515 | $840K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 21,241 | $822K |
| 84702 | <1% | 27,752 | $794K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,769 | $732K |
| 0710 | <1% | 2,999 | $731K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,575 | $710K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,164 | $706K |
| Z7502 | <1% | 19,006 | $678K | |
| 0300 | <1% | 380 | $675K | |
| 76801 | <1% | 3,941 | $633K | |
| 83690 | <1% | 28,525 | $630K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,570 | $613K |
| 0721 | <1% | 7,345 | $546K | |
| 93970 | <1% | 2,273 | $540K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,200 | $498K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,607 | $494K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,408 | $490K |
| 0250 | <1% | 2,752 | $472K | |
| 82962 | <1% | 29,348 | $470K | |
| 87040 | <1% | 5,777 | $463K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,480 | $436K |
| 93971 | <1% | 1,997 | $346K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 11,191 | $338K |
| 76830 | Ultrasound, transvaginal | <1% | 2,494 | $333K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,168 | $321K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,552 | $312K |
| 97139 | <1% | 8,080 | $282K | |
| 70486 | <1% | 808 | $279K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,227 | $262K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,338 | $248K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,535 | $195K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 420 | $175K |
| 73030 | <1% | 2,544 | $175K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,186 | $170K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,746 | $169K |
| 70496 | <1% | 355 | $165K | |
| 97799 | <1% | 4,134 | $162K | |
| 70498 | <1% | 320 | $159K | |
| 72100 | <1% | 2,331 | $155K | |
| 73562 | <1% | 2,640 | $147K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 342 | $146K |
| 83880 | <1% | 6,134 | $143K | |
| J3490 | Unclassified drugs | <1% | 2,329 | $137K |
| Z9725 | <1% | 3,148 | $135K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 857 | $131K |
| 73630 | <1% | 2,157 | $130K | |
| 85379 | <1% | 4,762 | $127K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,273 | $121K |
| 73610 | <1% | 1,894 | $120K | |
| 86900 | <1% | 4,598 | $110K | |
| 87631 | <1% | 2,554 | $104K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,238 | $104K |
| 97161 | <1% | 2,037 | $103K | |
| 83735 | <1% | 6,460 | $99K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,851 | $99K |
| 85610 | <1% | 8,547 | $98K | |
| 93798 | <1% | 1,671 | $94K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,500 | $93K |
| 76770 | <1% | 860 | $92K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,686 | $92K |
| 82077 | <1% | 2,572 | $92K | |
| 0258 | <1% | 2,988 | $91K | |
| 71250 | <1% | 389 | $88K | |
| 72040 | <1% | 1,125 | $88K | |
| 70491 | <1% | 185 | $87K | |
| 86901 | <1% | 4,585 | $87K | |
| 83605 | <1% | 5,870 | $87K | |
| 73130 | <1% | 1,279 | $75K | |
| 87081 | <1% | 2,883 | $74K | |
| 87186 | <1% | 5,776 | $72K | |
| 84703 | <1% | 5,687 | $70K | |
| 85730 | <1% | 6,822 | $64K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 235 | $63K |
| 81003 | <1% | 7,421 | $62K | |
| 0270 | <1% | 375 | $62K | |
| 0730 | <1% | 339 | $61K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,056 | $61K |
| 93976 | <1% | 319 | $57K | |
| 80143 | <1% | 1,449 | $55K | |
| 94799 | <1% | 1,632 | $55K | |
| 93458 | <1% | 51 | $54K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,502 | $53K |
| 0160 | <1% | 52 | $53K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 399 | $53K |
| 87077 | <1% | 6,371 | $52K | |
| 80179 | <1% | 1,416 | $52K | |
| 77412 | <1% | 793 | $51K | |
| 76870 | <1% | 338 | $51K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 800 | $50K |
| 84145 | <1% | 2,486 | $48K | |
| 0324 | <1% | 311 | $47K | |
| 77336 | <1% | 754 | $47K | |
| 73502 | <1% | 1,102 | $46K | |
| 73110 | <1% | 847 | $44K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,224 | $43K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,235 | $43K |
| 87510 | <1% | 2,590 | $42K | |
| 87480 | <1% | 2,595 | $42K | |
| 87660 | <1% | 2,598 | $42K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,115 | $41K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,220 | $41K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,699 | $41K |
| 96376 | <1% | 1,252 | $36K | |
| 75574 | <1% | 86 | $36K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,115 | $36K |
| 71101 | <1% | 453 | $35K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,456 | $35K |
| 97162 | <1% | 1,644 | $34K | |
| 74022 | <1% | 428 | $32K | |
| 94727 | <1% | 547 | $32K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 220 | $30K |
| 73080 | <1% | 502 | $29K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 78 | $29K |
| 90715 | <1% | 1,440 | $29K | |
| 82550 | <1% | 1,746 | $28K | |
| 86850 | <1% | 1,509 | $28K | |
| 74018 | <1% | 752 | $28K | |
| 0761 | <1% | 745 | $28K | |
| 0489 | <1% | 14 | $28K | |
| 73590 | <1% | 530 | $26K | |
| 94729 | <1% | 561 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 807 | $24K |
| 80061 | Lipid panel | <1% | 4,391 | $23K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,855 | $21K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,689 | $21K |
| 86140 | <1% | 2,077 | $21K | |
| 93017 | <1% | 166 | $21K | |
| 0420 | <1% | 114 | $21K | |
| 29125 | <1% | 335 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,705 | $20K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,099 | $20K |
| 72131 | <1% | 82 | $20K | |
| 84439 | <1% | 2,265 | $19K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,573 | $19K |
| 0760 | <1% | 380 | $19K | |
| 87070 | <1% | 1,163 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,189 | $18K |
| 85027 | <1% | 2,436 | $18K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,440 | $18K |
| 94060 | <1% | 164 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,717 | $17K |
| 88304 | <1% | 718 | $16K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,346 | $16K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 380 | $16K |
| 95816 | <1% | 173 | $16K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 588 | $15K |
| 86308 | <1% | 666 | $15K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,114 | $15K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 58 | $14K |
| 97803 | <1% | 352 | $13K | |
| 84550 | <1% | 2,018 | $13K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 124 | $13K |
| 85652 | <1% | 1,860 | $12K | |
| 83615 | <1% | 1,171 | $11K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,455 | $11K |
| 0352 | <1% | 12 | $11K | |
| 72072 | <1% | 121 | $11K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,818 | $10K |
| 94010 | <1% | 145 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,818 | $10K |
| 88307 | <1% | 132 | $10K | |
| 87427 | <1% | 295 | $9K | |
| 74174 | <1% | 13 | $9K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 375 | $9K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 595 | $9K |
| 0272 | <1% | 143 | $9K | |
| 73140 | <1% | 183 | $9K | |
| 73090 | <1% | 174 | $8K | |
| G0378 | Hospital observation service, per hour | <1% | 117 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,857 | $8K |
| 82728 | <1% | 2,864 | $8K | |
| 82570 | <1% | 2,769 | $8K | |
| 93975 | <1% | 37 | $7K | |
| V2632 | Posterior chamber intraocular lens | <1% | 336 | $7K |
| 82009 | <1% | 902 | $7K | |
| 87045 | <1% | 309 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,613 | $6K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 83 | $6K |
| 0370 | <1% | 288 | $6K | |
| 96367 | <1% | 129 | $6K | |
| 0402 | <1% | 13 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,004 | $6K |
| 97163 | <1% | 87 | $5K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 813 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,519 | $5K |
| 86141 | <1% | 302 | $5K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 462 | $5K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 32 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,011 | $4K |
| 87205 | <1% | 822 | $4K | |
| 97166 | <1% | 155 | $4K | |
| 87046 | <1% | 309 | $4K | |
| 97802 | <1% | 53 | $4K | |
| 83540 | <1% | 2,500 | $4K | |
| 73564 | <1% | 53 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,324 | $4K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 19 | $4K |
| 83970 | <1% | 652 | $4K | |
| 95819 | <1% | 25 | $4K | |
| 0320 | <1% | 13 | $4K | |
| 83550 | <1% | 2,389 | $3K | |
| 85670 | <1% | 124 | $3K | |
| 85347 | <1% | 164 | $3K | |
| 82607 | <1% | 1,703 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 748 | $3K |
| 85384 | <1% | 93 | $3K | |
| 74230 | <1% | 31 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 39 | $3K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 271 | $3K |
| 77334 | <1% | 16 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 181 | $2K |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 43 | $2K |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | <1% | 17 | $2K |
| Z7500 | <1% | 65 | $2K | |
| 71020 | <1% | 63 | $2K | |
| 84100 | <1% | 651 | $2K | |
| 92611 | <1% | 31 | $2K | |
| 87807 | <1% | 59 | $2K | |
| 73060 | <1% | 37 | $2K | |
| 73552 | <1% | 53 | $2K | |
| 29515 | <1% | 14 | $2K | |
| 12001 | <1% | 25 | $1K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 78 | $1K |
| 72110 | <1% | 13 | $1K | |
| 82043 | <1% | 1,598 | $1K | |
| 73660 | <1% | 26 | $1K | |
| 96415 | <1% | 22 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 72 | $1K |
| 80069 | <1% | 889 | $1K | |
| 82805 | <1% | 27 | $1K | |
| 87641 | <1% | 99 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 151 | $1K |
| 87634 | <1% | 28 | $1K | |
| 72070 | <1% | 12 | $1K | |
| 82746 | <1% | 491 | $998.70 | |
| 87147 | <1% | 124 | $940.15 | |
| 97116 | <1% | 102 | $922.44 | |
| 70360 | <1% | 16 | $878.26 | |
| V2630 | Anterior chamber intraocular lens | <1% | 40 | $846.21 |
| 87449 | <1% | 98 | $816.58 | |
| 71010 | <1% | 34 | $792.00 | |
| 82803 | <1% | 27 | $659.36 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $625.11 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 93 | $523.43 |
| 73620 | <1% | 12 | $510.55 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 51 | $497.72 |
| 82140 | <1% | 31 | $460.09 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 62 | $459.12 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 40 | $449.69 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 75 | $401.16 |
| 10060 | <1% | 13 | $386.04 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 15 | $356.07 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 78 | $293.62 |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | <1% | 115 | $280.46 |
| 87324 | <1% | 32 | $260.32 | |
| 82784 | <1% | 105 | $247.09 | |
| 80074 | <1% | 13 | $194.40 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 13 | $172.91 |
| 84153 | <1% | 40 | $142.62 | |
| 88300 | <1% | 15 | $138.04 | |
| J1815 | Injection, insulin, per 5 units | <1% | 35 | $129.33 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 27 | $117.39 |
| 87340 | <1% | 40 | $112.04 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 31 | $106.02 |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | <1% | 14 | $96.11 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 38 | $95.62 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 40 | $92.80 |
| 85007 | <1% | 12 | $85.62 | |
| Z7610 | <1% | 20 | $75.47 | |
| 87075 | <1% | 13 | $73.72 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 40 | $71.13 |
| 85045 | <1% | 26 | $69.96 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 15 | $32.90 |
| 82565 | <1% | 24 | $24.79 | |
| 84132 | <1% | 13 | $21.83 | |
| C1769 | Guide wire | <1% | 13 | $13.78 |
| 82378 | <1% | 24 | $11.82 | |
| 84165 | <1% | 13 | $5.55 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $4.37 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 15 | $0.01 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEVANS, WILLIAM (CHIEF STRATEGY OFFICER/MARKET CEO)
| Provider | Location | Paid |
|---|---|---|
| Cross Timbers Orthopaedics | Stephenville, TX | $6K |
| Evans Chiropractic PLLC | Muskogee, OK | $4K |
| Farr West Urgent Care and Family Medicine LLC | Farr West, UT | $704.55 |
| SJC Management & Consulting Corp | Pomona, CA | $2.62 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.